ASND

Ascendis Pharma A/S NASDAQ

Healthcare ·Biotechnology ·DK · ascendispharma.com

$228.71

Mkt Cap $14.0B

52w Low $150.89 77.9% of range 52w High $250.74

50d MA $231.14 200d MA $210.25

P/E (TTM) -61.0x

EV/EBITDA -98.8x

P/B —

Debt/Equity -5.3x

ROE —

P/FCF 252.2x

RSI (14) —

ATR (14) —

Beta 0.48

50d MA $231.14

200d MA $210.25

Avg Volume 717.4K

About

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapeutics for unmet medical needs. The company offers SKYTROFA for treating patients with growth hormone deficiency (GHD). It also develops TransCon Growth Hormone (hGH) for pediatric GHD in Japan; TransCon hGH for adults with GHD; TransCon parathyroid hormone for adult hypoparathyroidism; and TransCon CNP for pediatric ach…

Recent Earnings

Date	Time	Est	Rptd	Surp	Base	Gap%	D1%	D2%	D3%	D4%	D5%	1M%	Guide ▲★
Feb 11, 2026	AMC	-0.06	-0.64	-966.7%	221.49	-4.7%	-1.5%	-2.3%	+0.9%	+2.4%	+3.9%	+2.0%	—
Nov 12, 2025	AMC	-0.41	-1.17	-185.4%	199.22	-3.5%	+3.6%	+2.6%	+8.7%	+9.0%	+6.5%	+10.6%	—
Aug 7, 2025	AMC	-1.42	-0.93	+34.5%	190.35	+3.8%	+0.6%	+3.0%	+3.0%	+0.4%	+0.9%	+7.8%	—
May 1, 2025	AMC	-1.56	-1.66	-6.4%	167.47	+0.3%	+2.7%	+2.0%	-2.8%	-3.9%	-4.8%	+4.9%	—
Feb 12, 2025	AMC	-1.20	-0.68	+43.3%	126.14	+10.0%	+13.0%	+14.2%	+23.8%	+23.0%	+22.5%	+21.3%	—
Nov 14, 2024	AMC	-1.83	-1.81	+1.2%	124.28	-4.3%	+1.8%	-1.8%	+0.1%	+0.1%	-1.3%	+9.9%	—
Sep 3, 2024	AMC	-1.54	-2.05	-33.1%	134.68	-13.1%	-11.3%	-11.6%	-11.5%	-13.2%	-14.8%	+4.7%	—
May 2, 2024	AMC	-1.62	-2.48	-53.3%	141.10	+0.6%	-2.8%	-5.0%	-3.6%	-5.1%	-5.6%	-4.1%	—
Feb 7, 2024	AMC	-2.19	-1.66	+24.1%	139.29	+1.1%	-0.0%	+1.8%	+3.8%	+2.9%	+5.3%	+5.3%	—
Nov 7, 2023	AMC	-2.55	-3.08	-21.0%	96.15	-1.8%	-1.5%	-4.2%	-6.1%	-7.0%	-1.5%	+13.2%	—
Aug 16, 2023	AMC	-3.09	-1.54	+50.2%	89.90	+0.1%	-2.2%	+0.6%	+4.0%	+2.9%	+4.5%	+14.2%	—
Apr 27, 2023	AMC	-2.93	-2.18	+25.6%	76.98	-0.6%	-9.1%	+12.7%	+11.7%	+18.9%	+22.1%	+16.3%	—

Recent Analyst Ratings

Date	Firm	Action	Grade	Target	Base	Open	Gap%	D1%	D2%	D3%	D4%	D5%
Apr 16	BofA Securities	Maintains	Buy → Buy	—	$241.71	$241.71	+0.0%	+0.5%	+1.1%	+1.5%	-0.6%	-4.4%
Apr 9	Wedbush	Maintains	Outperform → Outperform	—	$233.20	$233.20	+0.0%	+3.6%	+2.6%	+6.6%	+7.1%	+3.6%
Mar 3	RBC Capital	Maintains	Outperform → Outperform	—	$242.09	$235.80	-2.6%	-1.2%	-0.3%	-2.0%	-0.6%	-0.9%
Feb 12	Oppenheimer	Maintains	Outperform → Outperform	—	$221.49	$211.00	-4.7%	-1.5%	-2.3%	+0.9%	+2.4%	+3.9%
Feb 12	Wedbush	Maintains	Outperform → Outperform	—	$221.49	$211.00	-4.7%	-1.5%	-2.3%	+0.9%	+2.4%	+3.9%
Jan 30	BofA Securities	Maintains	Buy → Buy	—	$223.95	$224.00	+0.0%	+1.0%	-0.2%	+0.3%	-1.9%	-2.9%
Jan 20	Wells Fargo	Maintains	Overweight → Overweight	—	$205.83	$203.51	-1.1%	+4.7%	+5.3%	+11.1%	+14.4%	+13.5%
Jan 20	RBC Capital	Maintains	Outperform → Outperform	—	$205.83	$203.51	-1.1%	+4.7%	+5.3%	+11.1%	+14.4%	+13.5%
Jan 9	Wells Fargo	Maintains	Overweight → Overweight	—	$208.75	$213.24	+2.2%	-2.8%	+0.0%	+3.0%	+4.1%	+3.0%
Jan 7	TD Cowen	Maintains	Buy → Buy	—	$209.29	$209.61	+0.2%	+1.9%	-0.3%	-3.0%	-0.3%	+2.8%
Dec 11	Stifel	Maintains	Buy → Buy	—	$201.24	$203.69	+1.2%	+4.4%	+9.5%	+6.0%	+5.4%	+0.8%
Nov 18	Wedbush	Maintains	Outperform → Outperform	—	$216.56	$221.89	+2.5%	+0.3%	-2.0%	-3.2%	-2.8%	-3.5%
Oct 13	Cantor Fitzgerald	Maintains	Overweight → Overweight	—	$209.55	$214.06	+2.2%	-0.5%	-0.4%	-1.2%	-1.2%	+0.5%
Oct 9	JP Morgan	Maintains	Overweight → Overweight	—	$210.13	$210.00	-0.1%	+2.2%	-0.3%	-0.8%	-0.7%	-1.4%
Sep 2	BofA Securities	Maintains	Buy → Buy	—	$194.27	$195.50	+0.6%	+2.5%	+3.0%	+2.0%	+6.0%	+5.6%
Aug 19	JP Morgan	Maintains	Overweight → Overweight	—	$194.08	$192.74	-0.7%	+0.3%	-0.7%	-0.7%	+0.1%	-1.9%
Aug 8	Cantor Fitzgerald	Maintains	Overweight → Overweight	—	$190.35	$197.58	+3.8%	+0.6%	+3.0%	+3.0%	+0.4%	+0.9%
Aug 8	Stifel	Maintains	Buy → Buy	—	$190.35	$197.58	+3.8%	+0.6%	+3.0%	+3.0%	+0.4%	+0.9%
Aug 8	Citigroup	Maintains	Buy → Buy	—	$190.35	$197.58	+3.8%	+0.6%	+3.0%	+3.0%	+0.4%	+0.9%
Aug 8	Wedbush	Maintains	Outperform → Outperform	—	$190.35	$197.58	+3.8%	+0.6%	+3.0%	+3.0%	+0.4%	+0.9%
Aug 8	RBC Capital	Maintains	Outperform → Outperform	—	$190.35	$197.58	+3.8%	+0.6%	+3.0%	+3.0%	+0.4%	+0.9%
Aug 8	UBS	Maintains	Buy → Buy	—	$190.35	$197.58	+3.8%	+0.6%	+3.0%	+3.0%	+0.4%	+0.9%
Aug 8	Wells Fargo	Maintains	Overweight → Overweight	—	$190.35	$197.58	+3.8%	+0.6%	+3.0%	+3.0%	+0.4%	+0.9%
Jul 29	JP Morgan	Maintains	Overweight → Overweight	—	$164.16	$164.27	+0.1%	-0.5%	+1.6%	+5.7%	+6.3%	+12.2%
Jul 11	Citigroup	Maintains	Buy → Buy	—	$176.49	$176.42	-0.0%	-0.9%	-0.9%	-1.0%	-0.6%	+0.4%
Jun 13	Oppenheimer	Maintains	Outperform → Outperform	—	$170.92	$170.18	-0.4%	-0.1%	+4.0%	+1.2%	-0.1%	+3.5%
Jun 9	BofA Securities	Maintains	Buy → Buy	—	$173.06	$175.85	+1.6%	+0.1%	-0.4%	-0.8%	-1.2%	-1.3%
Jun 3	BofA Securities	Maintains	Buy → Buy	—	$175.69	$176.34	+0.4%	-0.7%	-1.1%	+1.1%	-1.5%	-1.4%
May 12	Cantor Fitzgerald	Maintains	Overweight → Overweight	—	$151.25	$153.41	+1.4%	+2.1%	+6.8%	+3.9%	+4.2%	+4.2%
May 5	Morgan Stanley	Upgrade	Equal Weight → Overweight	—	$172.06	$175.60	+2.1%	-0.8%	-5.4%	-6.4%	-7.4%	-12.1%
May 2	RBC Capital	Maintains	Outperform → Outperform	—	$167.47	$168.00	+0.3%	+2.7%	+2.0%	-2.8%	-3.9%	-4.8%
May 2	Wedbush	Maintains	Outperform → Outperform	—	$167.47	$168.00	+0.3%	+2.7%	+2.0%	-2.8%	-3.9%	-4.8%
May 2	Oppenheimer	Maintains	Outperform → Outperform	—	$167.47	$168.00	+0.3%	+2.7%	+2.0%	-2.8%	-3.9%	-4.8%
May 2	Evercore ISI	Maintains	Outperform → Outperform	—	$167.47	$168.00	+0.3%	+2.7%	+2.0%	-2.8%	-3.9%	-4.8%
May 2	JP Morgan	Maintains	Overweight → Overweight	—	$167.47	$168.00	+0.3%	+2.7%	+2.0%	-2.8%	-3.9%	-4.8%
Mar 18	JP Morgan	Maintains	Overweight → Overweight	—	$168.84	$168.01	-0.5%	-2.5%	-1.7%	-3.3%	-1.7%	-0.5%
Feb 25	Cantor Fitzgerald	Maintains	Overweight → Overweight	—	$151.06	$151.94	+0.6%	+0.3%	+1.0%	+1.4%	+3.7%	+0.6%
Feb 18	Evercore ISI	Maintains	Outperform → Outperform	—	$144.08	$145.48	+1.0%	+8.4%	+7.7%	+7.3%	+5.8%	+4.8%
Feb 13	JP Morgan	Maintains	Overweight → Overweight	—	$126.14	$138.75	+10.0%	+13.0%	+14.2%	+23.8%	+23.0%	+22.5%
Feb 13	Goldman Sachs	Maintains	Buy → Buy	—	$126.14	$138.75	+10.0%	+13.0%	+14.2%	+23.8%	+23.0%	+22.5%
Feb 11	Cantor Fitzgerald	Maintains	Overweight → Overweight	—	$119.49	$118.22	-1.1%	+0.0%	+5.6%	+19.2%	+20.6%	+30.7%
Jan 29	JP Morgan	Maintains	Overweight → Overweight	—	$129.37	$129.94	+0.4%	-1.4%	-1.6%	+1.0%	-3.3%	-5.5%
Nov 15	Wedbush	Maintains	Outperform → Outperform	—	$124.28	$118.98	-4.3%	+1.8%	-1.8%	+0.1%	+0.1%	-1.3%
Nov 15	Cantor Fitzgerald	Maintains	Overweight → Overweight	—	$124.28	$118.98	-4.3%	+1.8%	-1.8%	+0.1%	+0.1%	-1.3%
Nov 15	TD Cowen	Maintains	Buy → Buy	—	$124.28	$118.98	-4.3%	+1.8%	-1.8%	+0.1%	+0.1%	-1.3%
Nov 15	Stifel	Maintains	Buy → Buy	—	$124.28	$118.98	-4.3%	+1.8%	-1.8%	+0.1%	+0.1%	-1.3%
Nov 15	Oppenheimer	Maintains	Outperform → Outperform	—	$124.28	$118.98	-4.3%	+1.8%	-1.8%	+0.1%	+0.1%	-1.3%
Nov 4	Cantor Fitzgerald	Maintains	Overweight → Overweight	—	$125.28	$127.20	+1.5%	+0.4%	+2.3%	+3.3%	+1.0%	-0.8%
Oct 23	JP Morgan	Maintains	Overweight → Overweight	—	$129.07	$128.73	-0.3%	-1.1%	+0.6%	+1.0%	+0.3%	-1.8%
Oct 21	TD Cowen	Maintains	Buy → Buy	—	$129.90	$130.44	+0.4%	-1.0%	-0.6%	-1.7%	-0.1%	+0.3%

Data updated apr 24, 2026 7:15pm · Source: massive.com